81.41
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
What makes Nuvalent Inc. stock price move sharplyTargeted 200 Percent Gain - Metal.it
Is Nuvalent Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC - Insider Monkey
What analysts say about Nuvalent Inc. stockExplosive earnings growth - PrintWeekIndia
What institutions are buying Nuvalent Inc. stock nowSky-high return potential - jammulinksnews.com
Nuvalent Inc. Stock Analysis and ForecastHigh-yield capital appreciation - Autocar Professional
What drives Nuvalent Inc. stock priceConsistent triple returns - Autocar Professional
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - The Malaysian Reserve
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating - TipRanks
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks
Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com Nigeria
Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener
How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):